Gastrin-releasing peptide (GRP) is a 27-ammno acid neuroendocrine hormone that may play a role in the pathophysiology of small cell lung carcinoma. GRP and bombesin, a structurally related peptide, stimulate the growth of some cultured cell types. C-terminal GRP peptide analogs were developed that inhibited 6 nM bombesin-induced [3H]thymidine incorporation into quiescent murine Swiss 3T3 cels, which routinely produced a 6-fold stimulation over the basal extent of incorporation. The peptides were also analyzed for their ca-
Gastrin-releasing peptide (GRP) is a 27-amino acid neuroendocrine hormone and a member of a family of structurally related peptides that elicit a broad array of biologic activities. These activities include regulation of smooth muscle contraction, stimulation of secretion, modulation of neural activity, and growth regulation (for review, see refs. 1 and 2). Growth regulation has received special interest because a number of observations suggest that GRP may be involved as an autocrine factor in the pathophysiology of small cell lung carcinoma (3) (4) (5) (6) (7) (8) . GRP antagonists have been found to inhibit the growth of human small cell lung carcinoma cells in vitro (8) and in murine xenografts in vivo (9) . Thus, GRP antagonists may have therapeutic potential. In other studies, GRP antagonists have helped to identify at least two subtypes of GRP receptors (10) that appear to be members of the large family of guanine nucleotide regulatory protein-coupled receptors.
The potential autocrine role of GRP in small cell lung carcinoma has stimulated substantial progress in the development of GRP antagonists (for review, see ref. 11 ). The receptor binding site on GRP is located in the C-terminal 8 amino acids of GRP where it is structurally identical to the homologous region of bombesin. Bombesin is a 14-residue amphibian peptide that reacts approximately equivalently to GRP in studies ofmammalian responses. The C-terminal Met is naturally amidated and is required for full biologic activity, although it does not appear to be required for binding (12) (13) (14) (15) (16) (17) (18) . Coy et al. (14, 15) replaced the terminal peptide bond with a reduced form, T(CH2NH), yielding a reasonably potent antagonist, [13T14,CH2NH]bombesin, and have further explored the use of the T bond to make more potent antagonists (11) . Other antagonists have been made by replacing the terminal Met-NH2 with either an alkyl ester (16) or an alkyl amide (17, 18) . Specific members of these three classes of antagonists have potencies 21 nM, which is the potency of the natural hormone.
We report structure-function studies reliant on incorporation of the reduced T bond in the C-terminal region. We hoped to increase the potency of [13'I14, CH2NH] bombesin by applying principles developed by Folkers et al. (19, 20) , who improved the activity of a substance P antagonist by introducing D-amino acids adjacent to the binding region. Our activity studies were performed using inhibition ofbombesininduced incorporation of [3H]thymidine into quiescent Swiss 3T3 cells. This approach contrasts with other antagonist development programs that have relied on measurements of competition receptor binding potency and/or amylase release. We also analyzed peptides for competitive binding. The Swiss 3T3 mitogenic response has been used to evaluate agonist and antagonist potencies (11) , but it has not been employed as a "primary" screen. We envisioned that the mitogenic antagonist response might be a more stringent test of antiproliferative activity. In general, the growth promoting property of GRP had been studied extensively on Swiss 3T3 cells (21) (22) (23) , murine colonic cancer cells (24) , and normal bronchial epithelial cells (25, 26) .
MATERIALS AND METHODS
Peptide Synthesis and Purification. The peptides were synthesized on an Applied Biosystems model 430A peptide synthesizer, using an improved version of Merrifield's solidphase method (27, 28 (29) . Boc-protected amino acids were coupled to the resin using a modified program to suit the [benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate] (BOP) coupling procedure (30) . The coupling protocol involved dissolving 1 mmol of Boc-protected amino acid, 1 mmol of BOP, and 1 ml of 1 M 1-methylimidazole in 7 ml of dimethyl formamide. The mixture was added to 0.5 mmol of resin, mixed for 1 h, and filtered. Afterwards, a series of dimethyl formamide and CH2Cl2 washes were performed. After the peptide was assembled on the resin, it was deblocked and cleaved from the resin with liquid HF containing 10% (vol/vol) anisole in a variation of the method described by Sakakibara et al. (31) . The peptide and resin were next washed with ethyl acetate and the peptide was extracted from the resin with an aqueous 1% acetic acid solution and lyophilized.
The peptides were then purified by reverse-phase HPLC using a Vydac (Hesperia, CA) 218TP1022 column on a Waters Delta-Prep 3000 system equipped with a Gilson model 116 ultraviolet detector. Purification was achieved by equilibrating the column with 0.1% trifluoroacetic acid in H20 and developing with a linear gradient of acetonitrile from 10 to 40% in 20 min at a flow rate of 20 ml/min. Samples were collected manually and checked for purity on a SpectraPhysics analytical reverse-phase HPLC system utilizing a Vydac 218TP54 column. A flow rate of 1.5 ml/min was employed using a 0.1% trifluoroacetic acid/acetonitrile gradient from 10 to 60% acetonitrile in 10 min. Purity was determined to be >98%. Peptides were stored as desiccated powders at -20°C. Just prior to analyses, peptides were solubilized and serially diluted in cell culture maintenance medium as defined below.
The composition of each peptide was assessed by amino acid analysis and fast atom bombardment (FAB)-mass spectroscopy. Amino acid analysis was performed by the following procedure. Approximately 1-10 nmol of peptide was placed into an acid-washed Pyrex tube. The peptide was hydrolyzed under a reduced N2 atmosphere with 6 M HCl and 1% phenol for 1 h at 150°C. The peptide was then dried with a 2:2:1 (vol/vol) mixture of ethanol/water/triethylamine and derivatized with a 7:1:1:1 solution of ethanol/water/ triethylamine/phenylisothiocyanate. The derivatized amino acids were then analyzed by reverse-phase HPLC. The sample of interest was dissolved in glycerol prior to analysis by FAB-mass spectroscopy. FAB-mass spectra were obtained on a VG Analytical (Manchester, U.K.) 70SQ mass spectrometer of EBQQ geometry using a VG Analytical 11-250J data system for data acquisition. The mass spectrometer was operated at 7-kV accelerating potential and a resolution of 1000 (10% valley definition). The FAB gun used in the experiments was Ion Tech (Teddington, U.K.) FABliN operating at a 7-kV potential and 1-mA current. Xenon was used as the bombardment gas at a source pressure of 1 x 10-5 millibar.
Bombesin and GRP were purchased from Peninsula Laboratories. 125I-labeled GRP (specific activity, 2 mCi/nmol; 1 Ci = 37 GBq) was purchased from Amersham.
Biological Activities. Swiss 3T3 cells (passage unknown) were a gift from E. Rozengurt (Imperial Cancer Research Fund, London). Cells were maintained by serial passage at 37°C in a humidified atmosphere containing 5% C02/95% air in Dulbecco's modified Eagle's medium/Ham's nutrient mixture F-12 (DMEM/F-12; Mediatech, Herndon, VA) supplemented with 10% (vol/vol) fetal bovine serum (lot 882050; Biologos, Naperville, IL) on plastic ware. Our passages [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were employed in these studies. Cells were judged free of mycoplasma by coculture on Vero cells followed by Hoechst stain and examination by fluorescence microscopy. All studies were performed on density-arrested quiescent cells. Cells were seeded at 1.5 x 104 cells per cm2 and cultured for 3 days. The medium was replaced with DMEM/F-12 containing 0.75% fetal bovine serum (maintenance medium) and culture was continued for 2 days, when peptide bioactivity analyses commenced.
Mitogenicity assays were performed by overlaying peptide solution in triplicate on cell monolayers in 96-well trays (Linbro). Cell culture was resumed for 18 h, then cultures were pulse-labeled for 2 h with 0.5 ,uCi of [CH3-3H]thymidine (6.7 Ci/mmol; New England Nuclear) per well. Inhibition ofbombesin-induced mitogenicity was performed similarly where test peptide solutions, generally log5 dilutions, were added in the presence of 6 nM bombesin. One of the peptides (Table 1 , structure 3, see Results) served as an interassay control. The monolayers were washed three times with ice-cold phosphatebuffered saline, fixed with ice-cold 40%6 methanol/12% acetic acid (vol/vol), rinsed with phosphate-buffered saline, solubilized with detergent, and mixed with scintillant (Ready Safe, Beckman), and radioactivity was determined by liquid scintillation counting (LKB, 30%o efficiency).
Binding was carried out similarly to published studies (32) (33) (34) . Peptides were serially diluted in maintenance medium and overlayed in triplicate on quiescent monolayers in 24-well trays in a total volume of 300 ,l containing 10W cells and 50 pM 125I-labeled GRP. Binding was carried out at 37°C for 30 min; whereupon, monolayers were washed three times with chilled maintenance medium, and solubilized with detergent, and radioactivity was determined (LKB, 55% efficiency).
RESULTS
Biological activity analyses for representative peptides are depicted in Figs. 1-3 . Fig. 1 demonstrates peptide-induced [3H]thymidine incorporation into quiescent Swiss 3T3 cells. Bombesin produced a dose-related stimulation of incorporation that maximized at :10 nM bombesin. GRP was =5-fold less potent (data not shown). In contrast, the other indicated peptides failed to stimulate incorporation over background and thus appeared to possess no intrinsic agonist activity. As seen in Fig. 1, 6 nM bombesin stimulated a near-maximal degree of [3H]thymidine incorporation where the extent of the incorporation was =6-fold greater than the no-addition control.
Thus, 6 nM bombesin was selected as the concentration upon which other peptides were evaluated for antagonist potency. Typically, 6 nM bombesin-induced incorporation yielded -1800 cpm per microtiter well, and the no-addition control gave 300 cpm. Representative antagonist screening results are shown in Fig. 2 . The results are expressed as percent [3H]thymidine incorporation, where 100% is the value obtained for 6 nM bombesin. As can be seen in Fig. 2 , peptide 3 yielded an IC50 value of 0.7 uM and peptide 13 yielded an IC50 value of 0.2 nM.
All the structures were evaluated for their capacity to compete for the binding of 125I-labeled GRP as exemplified in Fig. 3 .
Our complete analyses are summarized in 
